Preoperative ropivacaine injection is beneficial in pars plana vitrectomy

Article

Administering an injection of 5 mL of 0.75% ropivacaine before pars plana vitrectomy reduces postoperative discomfort in patients

Administering an injection of 5 mL of 0.75% ropivacaine before pars plana vitrectomy reduces postoperative discomfort in patients, reveals an investigation in the journal Retina.

The study, led by Dr Carl-Ludwig Schönfeld, Augenklinik Herzog Carl Theodor, Munich, Germany, included 60 patients each randomly assigned 0.75% ropivacaine with 75 IU of hyaluronidase as peribulbar injection of 1, 3, or 5 mL pre- or 5 mL postoperatively. There were also 30 control patients who didn’t receive any additional analgesic treatment, Both groups were compared 1, 3 and 24 hours postoperatively.

The control group experienced a higher rate of postoperative pain, compared to those in the ropivacine group. The 5 mL dosage of ropivacine was the most effective pain reliever, compared to the 1 mL or 3 mL injection. The injections provide a benefit in analgesic demand and postoperative discomfort.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.